Forskning i Bayer HealthCare

I 2009 blev 1.847 mio. euro, svarende til 67,3 procent af Bayer-koncernens forsknings- og udviklingsbudget, brugt inden for HealthCare delkoncernen. Med denne investering danner virksomheden grundlag for, at divisionerne Consumer Care, Medical Care, Animal Health og Bayer Schering Pharma AG Tyskland kan introducere endnu flere innovative produkter på det voksende marked for sundhed.

Forskningen i Bayer Schering Pharma AG* i Tyskland er koncentreret omkring bl.a. hæmatologi/kardiologi, onkologi, hormonbehandling hos praktiserende læger og billeddiagnostik. Hovedvægten ligger på områder med et højt terapibehov, hvor nye behandlingsformer er særligt vigtige.

Eksempler på nye aktive ingredienser fra den farmaceutiske forskning:

I Diabetes Care Divisionen fokuserer forskningen på at styrke kerneprodukterne og ekspansion inden for hurtigtvoksende og profitable markedssegmenter. Disse segmenter målrettes med brugervenlige apparater til måling af blodsukkeret, og som dækker de individuelle behov hos personer med diabetes. Divisionen undersøger også teknologier, der tillader løbende blodglukosekontrol, og – på længere sigt – muligheder for helt at fjerne behovet for at tage blodprøver. I denne sammenhæng er en licensaftale med Sontra Medical Corporation blevet udvidet; virksomhedens ultralydsbaserede SonoPrep®-teknologi øger muligheden for at scanne gennem huden.

Forskning i Animal Health Divisionen er målrettet antibiotika, midler mod parasitter og produkter til behandling af ikke-smitsomme sygdomme som nyresvigt og kongestive hjertelidelser.

21th edition

Tackling devastating diseases: Title story

Protection for weak hearts: New treatments for heart failure

Protein hunters in the brain: Molecular marker could support earlier and better diagnosis

Fighting cancer with tobacco: Personalized therapy - a new therapeutic strategy to combat lymph node cancer

Cooperation against cancer: Research alliance for better diagnosis and treatment of tumor diseases

Deep into the lungs: Potential new active substance formulation to help patients with cystic fibrosis

On the way to finding a top candidate: Bayer researchers build customized protein molecules for the treatment of serious diseases

The blood simulator: Virtual drug tests increase patient safety

20th edition

Fast track to safe drugs: Research programs for more effective drug development

Lungs under too much pressure: Riociguat: new active ingredient to combat difficult breathing

Repairs in the nanocosmos: Otto Bayer Prize awarded to Professor Thomas Carell

Glimmer of light for the eye: Artificial proteins to combat macular degeneration

Research networking: Bayer scientists involved in numerous international research collaborations

Hope of rapid pain relief: New approaches to gynecological therapies for chronic women’s diseases

19th edition

Anti-cancer medicine

A vice-like grip on the cytoskeleton: Sagopilone shows promise in combating tumors

Good detective work: Searching for active substances using RNA interference

Treating tumors by blocking hormones: New active ingredient for treatment of breast cancer

The replenishers: Cancer stem cells provide new understanding of tumor development

Formulation research

Visualizing memory loss: Early identification of Alzheimer’s

Tiny Trojan horses: Nanocapsules transport active ingredients directly to their site of action

Early protection: New study of acetylsalicylic acid in cardiovascular prevention

The sweet danger: Innovative blood glucose meters make life safer for diabetics

Multifaceted impact: Structural analysis of crystals is aiding in pharmaceutical resarch

18th edition

Substance which controls raised heart rates: Be calm my beating heart

Thrombosis live: A new microscope lets scientists see the vascular system in fine detail

Help for weak hearts: Search for active substances to combat serious cardiovascular disease

High-potential multitalent: Recent studies confirm: active ingredient of Aspirin® can protect against colorectal cancer

* The names "Bayer Schering Pharma" or "Schering" as used in this publication always refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively.